ProLynx: Hitting the links

ProLynx LLC has developed conjugate linkers that increase a drug's duration of action by releasing active therapeutics at consistent, preprogrammed rates. By doing so, the company thinks it can overcome the drawbacks of other conjugate technologies.

First-generation conjugates increase duration of action by covalently attaching active drug to a macromolecular carrier, such as PEG or serum albumin. But these bound carriers often reduce a drug's biological activity and preclude intracellular action, according to ProLynx co-founder and President Daniel Santi...